Marshall E. Cates
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Marshall E. Cates has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Thomas W. Woolley
Samford University Brock School of Business, Birmingham, Alabama
4 shared publicationsThomas W Woolley
Thomas W Woolley PhD, Professor of Statistics, School of Business, Samford University
3 shared publications- Kevin Pan
Department of Economics, Finance, and Quantitative Analysis, Samford University, Birmingham, AL, USA
2 shared publications Michael D. Hogue
2 shared publicationsTerri M Wensel
McWhorter School of Pharmacy, Samford University, Birmingham, AL, USA
2 shared publications- Thomas W. Woolley
Senior Associate Provost and Professor of Quantitative Methods, Samford University, Birmingham, Alabama
2 shared publications
Latest Publications
- Open Access
- 1 April 2026
- Published by American Association of Psychiatric Pharmacists (AAPP) in Mental Health Clinician
- Vol. 16 (2) , 49-53
Changes in student pharmacists’ self-perceived knowledge and confidence regarding suicide prevention as the result of instruction and training
Introduction: Trained pharmacists could play a key role in suicide prevention. Suicide prevention programs for pharmacists and students have been described in published literature. This study aimed to determine the effect of an online training program and a simulation on student pharmacists’ self-perceived knowledge and confidence regarding suicide prevention. Methods: Third-year student pharmacists participated in online Question, Persuade, and Refer (QPR) Gatekeeper training followed by a simulation using standardized patients with depression and suicidality. Students completed a 15-item survey that assessed self-perceived knowledge and confidence regarding suicide prevention before online training, after online training, and after the simulation (1 cohort). A Mann-Whitney U test and a two-sample t test of unequal variances were used to provide a conservative estimate of the statistical significance of between-stage differences. Results: Pre- and post-QPR training surveys were completed by 295 (100%) students. Postsimulation surveys were completed by 67 (90.5%) students in the 1-cohort group. Post-QPR scores were statistically significantly increased versus pre-QPR scores on all 15 items. Postsimulation scores were statistically significantly increased versus pre-QPR on 13 items. Postsimulation scores were statistically significantly less versus post-QPR scores on 13 items. Discussion: Student pharmacists’ self-perceived knowledge and confidence regarding suicide prevention were increased by QPR training. In general, their self-perceptions decreased after the simulation although they were still increased compared with baseline. The online training program and simulation had a positive impact on student pharmacists’ knowledge and confidence.
- 1 April 2026
- Published by American Association of Psychiatric Pharmacists (AAPP) in Mental Health Clinician
- Vol. 16 (2) , 49-53
Open AccessChanges in student pharmacists’ self-perceived knowledge and confidence regarding suicide prevention as the result of instruction and training
Introduction: Trained pharmacists could play a key role in suicide prevention. Suicide prevention programs for pharmacists and students have been described in published literature. This study aimed to determine the effect of an online training program and a simulation on student pharmacists’ self-perceived knowledge and confidence regarding suicide prevention. Methods: Third-year student pharmacists participated in online Question, Persuade, and Refer (QPR) Gatekeeper training followed by a simulation using standardized patients with depression and suicidality. Students completed a 15-item survey that assessed self-perceived knowledge and confidence regarding suicide prevention before online training, after online training, and after the simulation (1 cohort). A Mann-Whitney U test and a two-sample t test of unequal variances were used to provide a conservative estimate of the statistical significance of between-stage differences. Results: Pre- and post-QPR training surveys were completed by 295 (100%) students. Postsimulation surveys were completed by 67 (90.5%) students in the 1-cohort group. Post-QPR scores were statistically significantly increased versus pre-QPR scores on all 15 items. Postsimulation scores were statistically significantly increased versus pre-QPR on 13 items. Postsimulation scores were statistically significantly less versus post-QPR scores on 13 items. Discussion: Student pharmacists’ self-perceived knowledge and confidence regarding suicide prevention were increased by QPR training. In general, their self-perceptions decreased after the simulation although they were still increased compared with baseline. The online training program and simulation had a positive impact on student pharmacists’ knowledge and confidence.
- Open Access
- 31 December 2023
- Published by Asian Conference on Clinical Pharmacy in Research in Clinical Pharmacy
- Vol. 1 (2) , 137-143
Antidepressant Adherence in a Community Pharmacy Setting Before and After the Onset of the COVID-19 Pandemic
Tatum N. Carruth, Marshall E. Cates, Kevin Pan. R Clin Pharm 2023;1:137-43. https://doi.org/10.59931/rcp.23.0002
- 31 December 2023
- Published by Asian Conference on Clinical Pharmacy in Research in Clinical Pharmacy
- Vol. 1 (2) , 137-143
Open AccessAntidepressant Adherence in a Community Pharmacy Setting Before and After the Onset of the COVID-19 Pandemic
Tatum N. Carruth, Marshall E. Cates, Kevin Pan. R Clin Pharm 2023;1:137-43. https://doi.org/10.59931/rcp.23.0002
- Open Access
- 1 April 2022
- Published by American Association of Psychiatric Pharmacists (AAPP) in Mental Health Clinician
- Vol. 12 (2) , 86-88
Ambitious AAPP vision necessitates bold actions
As long-time psychiatric pharmacists and past presidents of the College of Psychiatric and Neurologic Pharmacists (now American Association of Psychiatric Pharmacists [AAPP]), we applaud the article written by our colleagues1 that outlines the vision of our specialty for the future. As the authors note, the organization has been setting the tone for the growth and evolution of our specialty for the past 25 years. We are now well-positioned in many ways to make substantial strides toward fulfilling our vision statement—A world where all individuals living with mental illness receive safe, appropriate, and effective treatment.2 The authors1 offer a bold image of what this vision looks like, and we greatly need this meaningful vision that drives us toward a common goal, establishes a standard of excellence, and bridges the present to the future.3 A famous quote from Joel A. Barker4 sums up our position on the matter: “Vision without action is merely a dream. Action without vision just passes the time. Vision with action can change the world.” However, as would be expected with an ambitious plan, there are inherent challenges that must be addressed to ensure success.The scope of what is being suggested is remarkable. It would be a monumental challenge for Board Certified Psychiatric Pharmacists (BCPPs) to be involved in providing care to all patients with psychiatric diagnoses. The Centers for Disease Control and Prevention has reported that 16.5% of adults and 8.4% of children received medication for their mental health in the previous 12 months according to surveys conducted in 2020 and 2019, respectively.5,6 That roughly translates to 42 million adults and 6 million children based on US Census Bureau data. In terms of treated patients with specific psychiatric disorders in 2020, there were 49 million with anxiety, 48 million with depression, 10 million with attention-deficit/hyperactivity disorder, and 10 million with bipolar disorder.7 In addition to the call for BCPPs to provide comprehensive medication management (CMM), which is inherently patient centric, the authors1 propose a population-level psychotropic medication stewardship approach designed to identify those patients who would most benefit from BCPP-provided CMM. Based on our own clinical experience as well as findings from various studies, the reality is that a substantial proportion of patients with psychiatric disorders who receive pharmacotherapy with psychiatric medications could benefit from CMM, whether related to initiation/modification/discontinuation of medication therapy, prevention/resolution of drug interactions or adverse effects, performance of laboratory/other monitoring, improvement of medication adherence, or other important issues. Specific examples supporting our assertion include the following: approximately 50% of patients with schizophrenia, MDD, or bipolar disorder are non-adherent with medication therapy8; psychiatric medication polypharmacy is quite common and occurs across a range of disorders9; and adverse drug events from psychiatric medication use results in tens of thousands of emergency department visits annually, approximately 20% of which lead to hospitalization.10Thus, the current situation is one in which relatively few patients with psychiatric disorders are receiving the necessary CMM services from BCPPs. Simply put, in order to fulfill the vision as put forth by the authors, we will need a vast expansion in the number of BCPPs. The 2 basic routes to board certification in the specialty field are traditional training or clinical experience. Over the past several years, there have been approximately 100 postgraduate year (PGY) 2 psychiatric pharmacy residency positions, with a fill rate close to 94%.11 Unless the number of residency positions (and applicants) increase, we can expect a steady addition of only about 100 psychiatric pharmacists per year to the workforce. While there are undoubtedly many pharmacists with enough practice experience in psychiatric pharmacy to meet eligibility requirements to sit for the BCPP certification examination, there could be a variety of barriers that prevent them from doing so, such as a lack of incentives from employers (eg, payment for examination/annual fee/recertification continuing education, salary increase, opportunity for advancement). The educational considerations that the authors delineate for pharmacy students, PGY1 residents, and practicing pharmacists are important drivers of crucial workforce expansion in that they can lead to increased numbers of BCPPs and support of psychotropic medication stewardship. We also agree with the authors1 that all colleges and schools of pharmacy should have a BCPP on faculty. Aside from providing pertinent instruction, these faculty members could be instrumental in developing and fostering students' interest in pursuing a career in psychiatric pharmacy.Another significant challenge is funding. In terms of reimbursement for services, pharmacists are still not recognized as providers by Medicare, and opportunities for payment to pharmacists for patient-care services provided through state Medicaid programs are generally limited.12-14 Although health insurance companies can choose to reimburse pharmacists for cognitive services, the fact of the matter is that they still inadequately cover mental health care despite mental health parity laws, and many mental health providers do not even accept insurance because of inadequate payment models.15 Unfortunately, payers are inclined to concentrate on the initial investment of reimbursing pharmacists for providing CMM instead of taking the long-term view, supported by multiple research studies, that improved patient outcomes will quickly lead to an overall decrease in the cost of patient care. Finally, while some health care systems such as the Veterans Health Administration have invested heavily in hiring psychiatric pharmacists, many health care...
- 1 April 2022
- Published by American Association of Psychiatric Pharmacists (AAPP) in Mental Health Clinician
- Vol. 12 (2) , 86-88
Open AccessAmbitious AAPP vision necessitates bold actions
As long-time psychiatric pharmacists and past presidents of the College of Psychiatric and Neurologic Pharmacists (now American Association of Psychiatric Pharmacists [AAPP]), we applaud the article written by our colleagues1 that outlines the vision of our specialty for the future. As the authors note, the organization has been setting the tone for the growth and evolution of our specialty for the past 25 years. We are now well-positioned in many ways to make substantial strides toward fulfilling our vision statement—A world where all individuals living with mental illness receive safe, appropriate, and effective treatment.2 The authors1 offer a bold image of what this vision looks like, and we greatly need this meaningful vision that drives us toward a common goal, establishes a standard of excellence, and bridges the present to the future.3 A famous quote from Joel A. Barker4 sums up our position on the matter: “Vision without action is merely a dream. Action without vision just passes the time. Vision with action can change the world.” However, as would be expected with an ambitious plan, there are inherent challenges that must be addressed to ensure success.The scope of what is being suggested is remarkable. It would be a monumental challenge for Board Certified Psychiatric Pharmacists (BCPPs) to be involved in providing care to all patients with psychiatric diagnoses. The Centers for Disease Control and Prevention has reported that 16.5% of adults and 8.4% of children received medication for their mental health in the previous 12 months according to surveys conducted in 2020 and 2019, respectively.5,6 That roughly translates to 42 million adults and 6 million children based on US Census Bureau data. In terms of treated patients with specific psychiatric disorders in 2020, there were 49 million with anxiety, 48 million with depression, 10 million with attention-deficit/hyperactivity disorder, and 10 million with bipolar disorder.7 In addition to the call for BCPPs to provide comprehensive medication management (CMM), which is inherently patient centric, the authors1 propose a population-level psychotropic medication stewardship approach designed to identify those patients who would most benefit from BCPP-provided CMM. Based on our own clinical experience as well as findings from various studies, the reality is that a substantial proportion of patients with psychiatric disorders who receive pharmacotherapy with psychiatric medications could benefit from CMM, whether related to initiation/modification/discontinuation of medication therapy, prevention/resolution of drug interactions or adverse effects, performance of laboratory/other monitoring, improvement of medication adherence, or other important issues. Specific examples supporting our assertion include the following: approximately 50% of patients with schizophrenia, MDD, or bipolar disorder are non-adherent with medication therapy8; psychiatric medication polypharmacy is quite common and occurs across a range of disorders9; and adverse drug events from psychiatric medication use results in tens of thousands of emergency department visits annually, approximately 20% of which lead to hospitalization.10Thus, the current situation is one in which relatively few patients with psychiatric disorders are receiving the necessary CMM services from BCPPs. Simply put, in order to fulfill the vision as put forth by the authors, we will need a vast expansion in the number of BCPPs. The 2 basic routes to board certification in the specialty field are traditional training or clinical experience. Over the past several years, there have been approximately 100 postgraduate year (PGY) 2 psychiatric pharmacy residency positions, with a fill rate close to 94%.11 Unless the number of residency positions (and applicants) increase, we can expect a steady addition of only about 100 psychiatric pharmacists per year to the workforce. While there are undoubtedly many pharmacists with enough practice experience in psychiatric pharmacy to meet eligibility requirements to sit for the BCPP certification examination, there could be a variety of barriers that prevent them from doing so, such as a lack of incentives from employers (eg, payment for examination/annual fee/recertification continuing education, salary increase, opportunity for advancement). The educational considerations that the authors delineate for pharmacy students, PGY1 residents, and practicing pharmacists are important drivers of crucial workforce expansion in that they can lead to increased numbers of BCPPs and support of psychotropic medication stewardship. We also agree with the authors1 that all colleges and schools of pharmacy should have a BCPP on faculty. Aside from providing pertinent instruction, these faculty members could be instrumental in developing and fostering students' interest in pursuing a career in psychiatric pharmacy.Another significant challenge is funding. In terms of reimbursement for services, pharmacists are still not recognized as providers by Medicare, and opportunities for payment to pharmacists for patient-care services provided through state Medicaid programs are generally limited.12-14 Although health insurance companies can choose to reimburse pharmacists for cognitive services, the fact of the matter is that they still inadequately cover mental health care despite mental health parity laws, and many mental health providers do not even accept insurance because of inadequate payment models.15 Unfortunately, payers are inclined to concentrate on the initial investment of reimbursing pharmacists for providing CMM instead of taking the long-term view, supported by multiple research studies, that improved patient outcomes will quickly lead to an overall decrease in the cost of patient care. Finally, while some health care systems such as the Veterans Health Administration have invested heavily in hiring psychiatric pharmacists, many health care...
- Open Access
- 1 January 2022
- Published by American Association of Psychiatric Pharmacists (AAPP) in Mental Health Clinician
- Vol. 12 (1) , 32-36
Istradefylline: A novel agent in the treatment of “off” episodes associated with levodopa/carbidopa use in Parkinson disease
The current gold standard for treatment of Parkinson disease (PD) is levodopa/carbidopa (L/C), but long-term treatment frequently results in motor complications, such as wearing-off and motor fluctuations (eg, dyskinesia, “on-off” phenomenon). Istradefylline is a new drug with a unique pharmacologic profile that was approved by the FDA for use as adjunctive treatment to L/C in adult patients with PD experiencing “off” episodes. The drug was shown to reduce “off” time in 4 randomized, double-blind, placebo-controlled studies. The most common adverse effects are dyskinesia, dizziness, constipation, nausea, hallucinations, and insomnia. Unlike many drugs that treat PD, istradefylline is a nondopaminergic drug that exerts its effects via adenosine A2A receptor antagonism. The major drug interactions involve inhibitors or inducers of CYP3A4 as well as tobacco smoking via induction of CYP1A1. Istradefylline is taken once daily as a 20- or 40-mg dose, except in cases involving drug interactions or hepatic impairment. The cost of the drug is relatively expensive, which has implications for Medicare and private insurance coverage. Istradefylline is an alternative option to dopaminergic drugs such as dopamine agonists, monoamine oxidase B inhibitors, and catechol-O-methyltransferase inhibitors as an adjunct to L/C in patients with motor fluctuations, but clinical use will further define its role in treatment of PD.
- 1 January 2022
- Published by American Association of Psychiatric Pharmacists (AAPP) in Mental Health Clinician
- Vol. 12 (1) , 32-36
Open AccessIstradefylline: A novel agent in the treatment of “off” episodes associated with levodopa/carbidopa use in Parkinson disease
The current gold standard for treatment of Parkinson disease (PD) is levodopa/carbidopa (L/C), but long-term treatment frequently results in motor complications, such as wearing-off and motor fluctuations (eg, dyskinesia, “on-off” phenomenon). Istradefylline is a new drug with a unique pharmacologic profile that was approved by the FDA for use as adjunctive treatment to L/C in adult patients with PD experiencing “off” episodes. The drug was shown to reduce “off” time in 4 randomized, double-blind, placebo-controlled studies. The most common adverse effects are dyskinesia, dizziness, constipation, nausea, hallucinations, and insomnia. Unlike many drugs that treat PD, istradefylline is a nondopaminergic drug that exerts its effects via adenosine A2A receptor antagonism. The major drug interactions involve inhibitors or inducers of CYP3A4 as well as tobacco smoking via induction of CYP1A1. Istradefylline is taken once daily as a 20- or 40-mg dose, except in cases involving drug interactions or hepatic impairment. The cost of the drug is relatively expensive, which has implications for Medicare and private insurance coverage. Istradefylline is an alternative option to dopaminergic drugs such as dopamine agonists, monoamine oxidase B inhibitors, and catechol-O-methyltransferase inhibitors as an adjunct to L/C in patients with motor fluctuations, but clinical use will further define its role in treatment of PD.
- Open Access
- 28 September 2020
- Published by IWA Publishing in Journal of Water and Health
- Vol. 18 (5) , 835-842
Association between concentrations of chromium in drinking water and mortality due to suicide in Alabama
Preclinical studies and clinical data from case series and placebo-controlled trials suggest that chromium might have antidepressant effects. We conducted an observational study in order to assess the association between concentrations of chromium in drinking water and mortality due to suicide in Alabama. Publicly available databases were used to determine both county-level concentrations of chromium in drinking water and county-level rates of mortality due to suicide in the years 2005–2015. Data analyses comparing county-level concentrations of total chromium in drinking water with mortality rate due to suicide were conducted using a two-tailed nonparametric Spearman's rank correlation, with statistical significance set at p ≤ 0.01 and 99% confidence interval. Sub-analyses were conducted examining males, females, whites, and blacks/other minorities. There were no statistically significant findings concerning concentrations of chromium and suicide rate in the general population (p = 0.35, r = −0.12); however, there was a statistically significant inverse relationship between the concentration of chromium and suicide deaths in whites (p = 0.009, r = −0.32). There were no statistically significant findings in the remaining demographic sub-groups. Chromium in drinking water might have a protective effect against mortality due to suicide, at least in the Caucasian population.
- 28 September 2020
- Published by IWA Publishing in Journal of Water and Health
- Vol. 18 (5) , 835-842
Open AccessAssociation between concentrations of chromium in drinking water and mortality due to suicide in Alabama
Preclinical studies and clinical data from case series and placebo-controlled trials suggest that chromium might have antidepressant effects. We conducted an observational study in order to assess the association between concentrations of chromium in drinking water and mortality due to suicide in Alabama. Publicly available databases were used to determine both county-level concentrations of chromium in drinking water and county-level rates of mortality due to suicide in the years 2005–2015. Data analyses comparing county-level concentrations of total chromium in drinking water with mortality rate due to suicide were conducted using a two-tailed nonparametric Spearman's rank correlation, with statistical significance set at p ≤ 0.01 and 99% confidence interval. Sub-analyses were conducted examining males, females, whites, and blacks/other minorities. There were no statistically significant findings concerning concentrations of chromium and suicide rate in the general population (p = 0.35, r = −0.12); however, there was a statistically significant inverse relationship between the concentration of chromium and suicide deaths in whites (p = 0.009, r = −0.32). There were no statistically significant findings in the remaining demographic sub-groups. Chromium in drinking water might have a protective effect against mortality due to suicide, at least in the Caucasian population.
- Open Access
- 1 January 2019
- Published by American Association of Psychiatric Pharmacists (AAPP) in Mental Health Clinician
- Vol. 9 (1) , 30-35
Pharmacists' attitudes, interest, and perceived skills regarding suicide prevention
Introduction: Pharmacists have been called upon to be involved in suicide prevention efforts, but little is known regarding their attitudes, interest, and perceived skills in the area. Methods: The study was a voluntary, anonymous survey of pharmacists who attended a large end-of-year continuing education program sponsored by a school of pharmacy. The survey included the Attitudes to Suicide Prevention (ASP) Scale, items concerning interest in suicide prevention, and items from the suicide skills section of the Suicide Knowledge and Skills Questionnaire. Results: The survey was completed by 227/297 (76.4%) pharmacists. The percentage of participants who expressed interest in direct involvement, indirect involvement, and receiving training in suicide prevention were 25%, 46%, and 56%, respectively. The mean total score on the ASP was 32.2 ± 5.5. Approximately 4% to 8% of participants agreed that they had the requisite training, skills, or support/supervision to engage and assist suicidal patients, and 22% agreed to feeling comfortable asking their patients direct and open questions about suicide. The ASP scores and items relating to perceived skills were correlated with interest in direct involvement in suicide prevention. Discussion: There were some positive findings, but overall, the pharmacists who participated in this survey felt unprepared to be frontline clinicians in suicide prevention efforts. Further studies should be conducted to determine if these findings are generally reflective of the broader pharmacy community. If the profession is to have a serious role in suicide prevention, then adequate suicide prevention training for pharmacy students and pharmacists may be necessary.
- 1 January 2019
- Published by American Association of Psychiatric Pharmacists (AAPP) in Mental Health Clinician
- Vol. 9 (1) , 30-35
Open AccessPharmacists' attitudes, interest, and perceived skills regarding suicide prevention
Introduction: Pharmacists have been called upon to be involved in suicide prevention efforts, but little is known regarding their attitudes, interest, and perceived skills in the area. Methods: The study was a voluntary, anonymous survey of pharmacists who attended a large end-of-year continuing education program sponsored by a school of pharmacy. The survey included the Attitudes to Suicide Prevention (ASP) Scale, items concerning interest in suicide prevention, and items from the suicide skills section of the Suicide Knowledge and Skills Questionnaire. Results: The survey was completed by 227/297 (76.4%) pharmacists. The percentage of participants who expressed interest in direct involvement, indirect involvement, and receiving training in suicide prevention were 25%, 46%, and 56%, respectively. The mean total score on the ASP was 32.2 ± 5.5. Approximately 4% to 8% of participants agreed that they had the requisite training, skills, or support/supervision to engage and assist suicidal patients, and 22% agreed to feeling comfortable asking their patients direct and open questions about suicide. The ASP scores and items relating to perceived skills were correlated with interest in direct involvement in suicide prevention. Discussion: There were some positive findings, but overall, the pharmacists who participated in this survey felt unprepared to be frontline clinicians in suicide prevention efforts. Further studies should be conducted to determine if these findings are generally reflective of the broader pharmacy community. If the profession is to have a serious role in suicide prevention, then adequate suicide prevention training for pharmacy students and pharmacists may be necessary.
- 1 September 2017
- Published by American Association of Psychiatric Pharmacists (AAPP) in Mental Health Clinician
- Vol. 7 (5) , 194-200
Effects of a psychiatric clinical rotation on pharmacy students' attitudes toward mental illness and the provision of pharmaceutical care to the mentally ill
Introduction: Previous studies have found ineffectiveness of psychiatric clinical rotations to change pharmacy students' attitudes toward mental illness, but those studies had various limitations that cast doubt on this conclusion.Methods: Pharmacy students who participated in a psychiatric clinical rotation over a 2-year time frame were invited to complete a survey at the beginning and end of their rotation. The survey included scales that measured attitudes toward dangerousness, social distance, stigmatization, suicide prevention, and provision of pharmaceutical care.Results: Forty-one (100%) students participated in the study. Statistically significant positive changes in total scale scores from pre-rotation to post-rotation were seen in the areas of stigmatization toward patients with schizophrenia (P = .02), attitudes toward suicide prevention (P = .05), and provision of pharmaceutical care services to patients with schizophrenia (P < .00001) and depression (P = .0006). There were no statistically significant changes on the total scores of the other scales, but there was a moderate improvement in stigmatization toward patients with depression.Discussion: Pharmacy students' participation in a psychiatric clinical rotation failed to have a major impact on their social distance from mentally ill patients. Findings were mixed in regards to stigmatization of mentally ill patients. However, pharmacy students' attitudes toward suicide prevention and providing pharmaceutical care services to mentally ill patients were significantly improved by participation in a psychiatric clinical rotation. Preceptors in the clinical setting should consider including educational techniques that address pharmacy students' attitudes toward mental illness, as improvement in such attitudes may further enhance their willingness to provide pharmaceutical care services.
- 1 September 2017
- Published by American Association of Psychiatric Pharmacists (AAPP) in Mental Health Clinician
- Vol. 7 (5) , 194-200
Effects of a psychiatric clinical rotation on pharmacy students' attitudes toward mental illness and the provision of pharmaceutical care to the mentally ill
Introduction: Previous studies have found ineffectiveness of psychiatric clinical rotations to change pharmacy students' attitudes toward mental illness, but those studies had various limitations that cast doubt on this conclusion.Methods: Pharmacy students who participated in a psychiatric clinical rotation over a 2-year time frame were invited to complete a survey at the beginning and end of their rotation. The survey included scales that measured attitudes toward dangerousness, social distance, stigmatization, suicide prevention, and provision of pharmaceutical care.Results: Forty-one (100%) students participated in the study. Statistically significant positive changes in total scale scores from pre-rotation to post-rotation were seen in the areas of stigmatization toward patients with schizophrenia (P = .02), attitudes toward suicide prevention (P = .05), and provision of pharmaceutical care services to patients with schizophrenia (P < .00001) and depression (P = .0006). There were no statistically significant changes on the total scores of the other scales, but there was a moderate improvement in stigmatization toward patients with depression.Discussion: Pharmacy students' participation in a psychiatric clinical rotation failed to have a major impact on their social distance from mentally ill patients. Findings were mixed in regards to stigmatization of mentally ill patients. However, pharmacy students' attitudes toward suicide prevention and providing pharmaceutical care services to mentally ill patients were significantly improved by participation in a psychiatric clinical rotation. Preceptors in the clinical setting should consider including educational techniques that address pharmacy students' attitudes toward mental illness, as improvement in such attitudes may further enhance their willingness to provide pharmaceutical care services.
- 1 March 2017
- Published by American Association of Psychiatric Pharmacists (AAPP) in Mental Health Clinician
- Vol. 7 (2) , 88-94
D-cycloserine in the treatment of posttraumatic stress disorder
Introduction: Posttraumatic stress disorder (PTSD) is a common and serious psychiatric illness. Exposure therapy is a type of cognitive behavioral therapy that is considered a first-line treatment option for PTSD. D-cycloserine (DCS) enhances fear extinction/exposure therapy in patients with various anxiety disorders, presumably via its N-methyl-D-aspartate receptor partial agonist effects. The aim of this paper is to review the published literature regarding the efficacy of DCS in the treatment of PTSD.Methods: A literature search for placebo-controlled trials assessing the use of DCS as the primary study drug in PTSD was conducted for trials published before June 2015 using PubMed, Ovid International Pharmaceutical Abstracts, and www.clinicaltrials.gov. The search terms were variations of “cycloserine” and “posttraumatic stress disorder.”Results: Seven clinical trials were analyzed, including 2 trials comparing DCS with placebo as add-on treatment to ongoing stable pharmacotherapy and 5 trials that compared DCS with placebo given prior to exposure therapy. D-cycloserine as adjunctive therapy showed no benefit in 1 trial and limited benefit in the other. As an enhancement of exposure therapy, DCS showed beneficial effects in 1 trial, detrimental effects in 1 trial, and inconclusive effects in 3 trials.Discussion: Current literature does not adequately support the use of DCS as adjunctive therapy without psychotherapy, but limitations of the 2 studies that exist make firm conclusions unfeasible. D-cycloserine might have a role in augmentation of exposure therapy. Future studies should consider receptor selectivity, administration time with respect to peak cerebrospinal fluid concentrations, number of exposure therapy sessions, and dose.
- 1 March 2017
- Published by American Association of Psychiatric Pharmacists (AAPP) in Mental Health Clinician
- Vol. 7 (2) , 88-94
D-cycloserine in the treatment of posttraumatic stress disorder
Introduction: Posttraumatic stress disorder (PTSD) is a common and serious psychiatric illness. Exposure therapy is a type of cognitive behavioral therapy that is considered a first-line treatment option for PTSD. D-cycloserine (DCS) enhances fear extinction/exposure therapy in patients with various anxiety disorders, presumably via its N-methyl-D-aspartate receptor partial agonist effects. The aim of this paper is to review the published literature regarding the efficacy of DCS in the treatment of PTSD.Methods: A literature search for placebo-controlled trials assessing the use of DCS as the primary study drug in PTSD was conducted for trials published before June 2015 using PubMed, Ovid International Pharmaceutical Abstracts, and www.clinicaltrials.gov. The search terms were variations of “cycloserine” and “posttraumatic stress disorder.”Results: Seven clinical trials were analyzed, including 2 trials comparing DCS with placebo as add-on treatment to ongoing stable pharmacotherapy and 5 trials that compared DCS with placebo given prior to exposure therapy. D-cycloserine as adjunctive therapy showed no benefit in 1 trial and limited benefit in the other. As an enhancement of exposure therapy, DCS showed beneficial effects in 1 trial, detrimental effects in 1 trial, and inconclusive effects in 3 trials.Discussion: Current literature does not adequately support the use of DCS as adjunctive therapy without psychotherapy, but limitations of the 2 studies that exist make firm conclusions unfeasible. D-cycloserine might have a role in augmentation of exposure therapy. Future studies should consider receptor selectivity, administration time with respect to peak cerebrospinal fluid concentrations, number of exposure therapy sessions, and dose.
- 1 February 2015
- Published by Elsevier in American Journal of Pharmaceutical Education
- Vol. 79 (1) , 09
Sleep Quality Among Pharmacy Students
To determine the quality of sleep among pharmacy students in the didactic portion of the curriculum at one school of pharmacy. The study consisted of an anonymous, voluntary survey that included the Pittsburgh Sleep Quality Index (PSQI), a self-rated instrument that measures sleep habits for a month. The survey was completed by 253 students. Students in the lower grade point average (GPA) category had higher scores on 2 of 7 components of the PSQI and on the global score. Poor sleep quality, indicated by a global PSQI score of greater than 5, was reported by 140 students. The rate of poor sleeping was higher among students in the lower GPA category. Poor sleep quality was pervasive among surveyed pharmacy students in the didactic portion of the pharmacy school curriculum, especially among those with lower GPAs.
- 1 February 2015
- Published by Elsevier in American Journal of Pharmaceutical Education
- Vol. 79 (1) , 09
Sleep Quality Among Pharmacy Students
To determine the quality of sleep among pharmacy students in the didactic portion of the curriculum at one school of pharmacy. The study consisted of an anonymous, voluntary survey that included the Pittsburgh Sleep Quality Index (PSQI), a self-rated instrument that measures sleep habits for a month. The survey was completed by 253 students. Students in the lower grade point average (GPA) category had higher scores on 2 of 7 components of the PSQI and on the global score. Poor sleep quality, indicated by a global PSQI score of greater than 5, was reported by 140 students. The rate of poor sleeping was higher among students in the lower GPA category. Poor sleep quality was pervasive among surveyed pharmacy students in the didactic portion of the pharmacy school curriculum, especially among those with lower GPAs.